Literature DB >> 25899660

Haemolytic disease of the fetus and newborn.

M de Haas1,2, F F Thurik2, J M Koelewijn2,3, C E van der Schoot2.   

Abstract

Haemolytic Disease of the Fetus and Newborn (HDFN) is caused by maternal alloimmunization against red blood cell antigens. In severe cases, HDFN may lead to fetal anaemia with a risk for fetal death and to severe forms of neonatal hyperbilirubinaemia with a risk for kernicterus. Most severe cases are caused by anti-D, despite the introduction of antental and postnatal anti-D immunoglobulin prophylaxis. In general, red blood cell antibody screening programmes are aimed to detect maternal alloimmunization early in pregnancy to facilitate the identification of high-risk cases to timely start antenatal and postnatal treatment. In this review, an overview of the clinical relevance of red cell alloantibodies in relation to occurrence of HDFN and recent views on prevention, screening and treatment options of HDFN are provided.
© 2015 International Society of Blood Transfusion.

Entities:  

Keywords:  RBC antigens and antibodies; alloimmunisation in pregnancy; anti-D prophylaxis; fetal genotyping; haemolytic disease of the fetus and newborn

Mesh:

Substances:

Year:  2015        PMID: 25899660     DOI: 10.1111/vox.12265

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  40 in total

1.  Single-stranded DNA aptamer targeting and neutralization of anti-D alloantibody: a potential therapeutic strategy for haemolytic diseases caused by Rhesus alloantibody.

Authors:  Yinze Zhang; Fan Wu; Manni Wang; Naibao Zhuang; Huayou Zhou; Hua Xu
Journal:  Blood Transfus       Date:  2016-11-11       Impact factor: 3.443

2.  Antibody-mediated immune suppression by antigen modulation is antigen-specific.

Authors:  Cheryl L Maier; Amanda Mener; Seema R Patel; Ryan P Jajosky; Ashley L Bennett; Connie M Arthur; Jeanne E Hendrickson; Sean R Stowell
Journal:  Blood Adv       Date:  2018-11-13

3.  Non-invasive foetal RhD genotyping in admixed populations.

Authors:  Frederik B Clausen
Journal:  Blood Transfus       Date:  2016-03-21       Impact factor: 3.443

4.  Determination of Fetal RHD Genotype Including the RHD Pseudogene in Maternal Plasma.

Authors:  Karen Chinoca Ziza; Adolfo Wenjaw Liao; Marcia Dezan; Carla Luana Dinardo; Eduardo Jens; Rossana Pulcineli Vieira Francisco; Alfredo Mendrone Junior; Marcelo Zugaib; José Eduardo Levi
Journal:  J Clin Lab Anal       Date:  2016-09-06       Impact factor: 2.352

5.  The Incidence and Effects of Alloimmunization in Pregnancy During the Period 2000 - 2013.

Authors:  Marjana Jerković Raguž; Darinka Šumanovic Glamuzina; Jerko Brzica; Tonći Gruica
Journal:  Geburtshilfe Frauenheilkd       Date:  2017-07-17       Impact factor: 2.915

6.  Prenatal non-invasive foetal RHD genotyping: diagnostic accuracy of a test as a guide for appropriate administration of antenatal anti-D immunoprophylaxis.

Authors:  Silvia Manfroi; Chiara Calisesi; Pietro Fagiani; Annalisa Gabriele; Gianluca Lodi; Simonetta Nucci; Susanna Pelliconi; Laura Righini; Vanda Randi
Journal:  Blood Transfus       Date:  2018-04-09       Impact factor: 3.443

7.  Genotyping approach for non-invasive foetal RHD detection in an admixed population.

Authors:  Carolina Trucco Boggione; Melina E Luján Brajovich; Stella M Mattaloni; René A Di Mónaco; Silvia E García Borrás; Claudia S Biondi; Carlos M Cotorruelo
Journal:  Blood Transfus       Date:  2016-03-21       Impact factor: 3.443

8.  Delayed cord clamping in red blood cell alloimmunization: safe, effective, and free?

Authors:  Ryan M McAdams
Journal:  Transl Pediatr       Date:  2016-04

Review 9.  Potential of Next-Generation Sequencing in Noninvasive Fetal Molecular Blood Group Genotyping.

Authors:  Sandra Wienzek-Lischka; Sandy Bachmann; Vanessa Froehner; Gregor Bein
Journal:  Transfus Med Hemother       Date:  2020-01-20       Impact factor: 3.747

10.  Severe haemolytic disease of a newborn with variant D mimicking blocked-D phenomenon.

Authors:  Soumya Das; Shamee Shastry; Poornima B Baliga
Journal:  BMJ Case Rep       Date:  2019-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.